Aligos Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a stark dichotomy between clinical promise and financial instability. On the scientific front, Aligos is hitting key markers with pevifoscorvir sodium, moving into a pivotal Phase 2 study that could fundamentally re-rate the company's value. The Amoytop deal serves as a vital bridge, providing both cash and a professional endorsement of the company's capsid assembly modulator platform. However, the financial reality is a race against time. The 'going concern' warning is the dominant signal for investors, suggesting that the clinical success of the B-SUPREME trial must arrive before the cash reserves vanish. Investors are essentially betting on a binary outcome: either the company secures a major new partnership or a successful equity raise based on interim data, or it faces a severe liquidity crisis before the 2027 topline results are released.